|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | 抑制平滑肌的张力收缩:一种治疗勃起功能障碍的新途径显示文摘阴茎海绵体血管的收缩及张力的维持是由钙敏感的RhoA/Rho激酶信号传导途径介导的。以Y 2 76 32抑制海绵体平滑肌细胞的Rho激酶信号系统可促进阴茎勃起 ,表现为海绵体内压 (ICP)明显升高 ,而平均动脉压 (MAP)变化不显著。为什么在血管收缩信号很强的情况下性刺激仍能引发阴茎勃起反应 ?我们设想体内一氧化氮 (NO)能直接抑制RhoA/Rho激酶途径的活性 ,减少血管张力 ,促使血管舒张 ,勃起发生 ,使用Y 2 76 32可以恢复性腺功能低下和高血压病动物ED模型的阴茎勃起功能 ,这表明抑制Rho激酶活性药物具有临床应用的前景。此外 ,我们的结果显示阴茎表面使用Rho激酶抑制剂可能为ED治疗的有效方法之一。 | 戴玉田 Thomas M MILLS Ronald W LEWIS RClinton WEBB | 2002 | 中华男科学杂志2002，8，6： | 8 |
| 3 | Mycophenolate mofetil for maintenance of remission in steroid-dependent autoimmune pancreatitis显示文摘Systemic corticosteroids represent the standard treatment for autoimmune pancreatitis with IgG4-associated cholangitis.For steroid-dependent disease,azathioprine has been used for maintenance of remission.Mycophenolate mofetil has been used for transplant immunosuppression and more recently for autoimmune hepatitis;however,there are no case reports to date on the use of mycophenolate mofetil in adult patients with autoimmune pancreatitis.A patient with IgG4-mediated autoimmune pancreatitis and IgG4-associated cholangitis refractory to steroids and intolerant of azathioprine was treated with mycophenolate mofetil,which inhibits de novo guanosine synthesis and blockade of both B and T lymphocyte production.Introduction of mycophenolate mofetil and uptitration to 1000 mg by mouth twice daily over a treatment period of 4 mo was associated with improvement in the patient's energy level and blood glucose control and was not associated with any adverse events.The patient was managed without a biliary stent.However,there was a return of symptoms,jaundice,increase in transaminases,and hyperbilirubinemia when the prednisone dose reached 11 mg per day.In the first report of mycophenolate mofetil use in an adult patient with IgG4-associated autoimmune pancreatitis and IgG4-associated cholangitis,the introduction of mycophenolate mofetil was safe and well-tolerated without adverse events,but it did not enable discontinuation of the steroids.Mycophenolate mofetil and other immunomodulatory therapies should continue to be studied for maintenance of remission in the large subset of patients with refractory or recurrent autoimmune pancreatitis. | Jamie B Sodikoff Steven A Keilin Sheila J Bharmal Melinda M Lewis Gottumukkala S Raju Field F Willingham | 2012 | World Journal of Gastroenterology2012，18，18： | 6 |
| 4 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 5 | 评估超高温灭菌奶安全和质量的2个重要参数显示文摘使用了一套电子程序表格,用于评估在连续热交换器中经过不同升温和降温处理后牛奶的安全和质量参数。安全参数包括致死率F0值、微生物灭活B*值;质量参数包括化学变化C*值、硫胺素损失量、乳果糖生成量、美拉德褐变及羟甲基糠醛值等。在牛奶中试加工车间中,利用升温和降温的温度变化数值可对牛奶的上述参数进行预测,温度范围为120~150℃,时间包括4、27和58 s。在同一中试车间按上述条件对牛奶进行加工,并选择一系列牛奶样品对该电子程序进行校正。结果表明,所有C*〈3的牛奶样品阿沙芬堡浊度都呈阳性。在乳果糖活化能等于122 k J/mol时,预测值和试验观测值一致性最好。最佳质量终产品对应的牛奶加工条件为135℃/10 s,此时B*=1.24,C*=0.55。在此条件下加工的牛奶与其它2个牛奶相比,感官特性与C*=1.5对应条件下加工的牛奶类似,但与C*=6对应条件下加工的牛奶不同。牛奶刚加工完成时,仅热处理非常强烈的样品有可见的褐变,若在≥30℃条件下存储,褐变会变得比较明显。该电子程序可以用来比较不同热处理模式下生产产品的特性;或作为一种手段,用于在升温和降温速率固定的情况下UHT设备运行条件的优化。 | 陈美霞 Browning E Lewis M Macdougall D | 2016 | 中国乳业2016，，5： | 3 |
| 6 | The use of adjoint equations to solve a variational adjustment problem with advective constrains 显示文摘 | Lewis J M Derber C | 1985 | Tellus1985，37，4： | 2 |
| 7 | Evaluation of contact resistance for isotropic electrically conductive adhesives 显示文摘 | Gaynes M A Lewis R H | 1995 | IEEE Trans Compon Packg Manuf Tech Part B1995，18，3： | 2 |
| 8 | Adaptive fuzzy logic control of discrete-time dynamical systems 显示文摘 | Jagannathan A Vandegrift M W Lewis F L | 2000 | Automatica2000，36，2： | 2 |
| 9 | Critical design issues for airbreathing hypersonic waverider missiles 显示文摘 | Ryan P Starkey M Lewis J | 2001 | Journal of Spacecraft and Rockets2001，38，4： | 1 |
| 10 | Robust Adaptive Control of Induction Motors Without Flux Measurment显示文摘 | Kwan C M Lewis F L Yeung K S | 1995 | ACC1995，32，6： | 1 |
| 11 | Thiazolo pyrimidines: 1 : synthesis and anti-human cytomegalovirus (HCMV) activity in-vitro of certain alkyl derivatives显示文摘 | Lewis A F Revankar G R Fennewald S M | 1995 | J Heterocycl Chem1995，32，20： | 1 |
| 12 | Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling 显示文摘 | Lewis HD Leveridge M Strack PR | 2007 | Chem Biol2007，14，2： | 1 |
| 13 | Human immunodeficiency virus infection of cells arrested in the cell cycle显示文摘 | Hensel M Emerman M | 1992 | EMBO J1992，11，8： | 1 |
| 14 | Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy显示文摘 | LI X LEWIS M T HUANG J | 2008 | J Natl Cancer Inst2008，100，9： | 1 |
| 15 | Toxicity comparison of biosurfactants and synthetic surfactants used in oil spill remediation to two estuarine species显示文摘 | Edwards K R Lepo J E Lewis M A | 2003 | Marine Pollution Bulletin2003，46，10： | 1 |
| 16 | Early enteral feeding versus 'nil by mouth′after gastrointestinal surgery:systematic review and meta-analysis of controlled trials显示文摘 | Lewis SJ Egger M Sylvester PA | 2001 | BMJ2001，323，7316： | 1 |
| 17 | Super-resolution land cover pattern prediction using a Hopfield neural network 显示文摘 | TATEM A J LEWIS H G ATKINSON P M NIXON M S | 2002 | Remote Sensing of Environment2002，，： | 1 |
| 18 | Improved Surface Properties of Polymer Materisls by Multiple Lon Beam Treatment显示文摘 | Lee E H Lewis M B Blau P J | 1991 | Mater Res1991，6，3： | 1 |
| 19 | Handmade somatic cell cloning in cattle:analysis of factors contributing to high efficiency in vitro显示文摘 | Vajta G Lewis I M Trounson A O | 2003 | Biol Reprod2003，68，2： | 1 |
| 20 | Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center:an autopsy study over a 15-year period (1989-2003)显示文摘 | Chamilos G Luna M Lewis RE | 2006 | Haematologica2006，91，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员